Silence Therapeutics Reports Steep Revenue Decline, Doubled Net Loss, and AstraZeneca Drops SLN312 Program

summarizeSummary

Silence Therapeutics announced significantly worse financial results for 2025, including a near-total collapse in collaboration revenue and a doubled net loss, alongside the termination of AstraZeneca's development of SLN312.

check_boxKey Events

• Steep Revenue Decline

  Collaboration revenue fell dramatically from $43.3 million in 2024 to $0.6 million for the full year ended December 31, 2025.

• Net Loss Doubled

  The company's net loss increased to $88.6 million for 2025, nearly doubling from $45.3 million in 2024.

• AstraZeneca Terminates SLN312 Development

  AstraZeneca notified Silence Therapeutics that it will not pursue further development of SLN312 beyond Phase 1, returning exclusive global rights to Silence.

• Cash Position Decreased

  Cash, cash equivalents, and short-term investments declined to $85.1 million as of December 31, 2025, from approximately $147.3 million in 2024.

auto_awesomeAnalysis

Silence Therapeutics' financial health has deteriorated significantly, with collaboration revenue plummeting and net losses nearly doubling year-over-year. This indicates a substantial cash burn and raises concerns about future funding and operational runway. The decision by AstraZeneca to cease development of SLN312 is a major setback for Silence's pipeline, as it loses a key partner for a clinical asset. While the accelerated timeline for Divesiran's Phase 2 results is a positive, it is heavily overshadowed by the severe financial performance and the loss of a significant partnership. Investors should monitor the company's cash runway and its strategy for SLN312 and other pipeline assets.